Capsular contracture: risks, prevention and follow-up after breast implants

A thin layer of scar tissue, called a capsule, normally forms around a breast implant. Capsular contracture describes an abnormal tightening of that tissue, which may make the breast feel firm, look different or become painful. It can affect one or both breasts and may appear months or years after surgery. It is not possible to predict with certainty who will develop it, and changes in an implanted breast need clinical assessment rather than self-diagnosis. A clinical review of current concepts describes several interacting mechanisms; the FDA likewise says the cause is not known.

This article distinguishes primary cosmetic augmentation from revision and reconstruction. Evidence from a breast-cancer reconstruction cohort, for example, cannot be used as a direct estimate for someone having a first cosmetic augmentation. Even studies of augmentation differ in implant surface, pocket, incision, diagnosis threshold and length of follow-up.

What causes the capsule to tighten?

Capsule formation is part of the body's response to an implanted foreign object. Contracture occurs when the response becomes excessive: the scar tissue can thicken and tighten around the device. Reviews describe chronic inflammation and bacterial contamination or biofilm as possible contributors, alongside patient, implant and surgical factors. These are interacting hypotheses, not a single proven cause for every case. Finding bacteria in some capsules does not show that every contracture is an infection, and a proposed risk factor does not establish that a particular surgeon or patient action caused an individual complication.

The US Food and Drug Administration (FDA) describes contracture as tightening of the capsule that can cause firmness or hardening and, when severe, squeeze the implant. It notes possible associations with infection, haematoma and seroma while stating that the cause is not known. Research also considers implant surface, pocket plane, incision, tissue coverage and other operative details. These factors should be interpreted as evidence about groups, not as a personal risk calculation. Safran and colleagues discuss these proposed mechanisms and associations.

How strong is the evidence on risk?

Reported rates depend on what a study calls contracture. Some count only Baker grades III and IV; others include milder firmness, and some report events per implant while others report people affected. A pooled percentage from one definition or follow-up period is not an individual's forecast.

A 10-year analysis of Sientra clinical-study data included 2,565 primary augmentation patients, 5,122 implants and 34 surgeons. Researchers reported 333 contracture events in 224 patients. The Kaplan–Meier estimate was 10.8% per device through ten years. Calobrace and colleagues report this manufacturer-specific cohort. In multivariable analyses, implant placement, surface, incision, haematoma or seroma, device size, surgical bra, steroid use and antibiotic pocket irrigation were independently associated with contracture (all P<.05). The authors described smooth surface, smaller size, periareolar incision, subglandular placement, haematoma or seroma, surgical bra and antibiotic irrigation among associated factors. This was a manufacturer-specific clinical dataset; association does not prove that any single factor caused an event, and its estimate should not be treated as a universal rate for all devices or current practice.

A broader 2026 systematic review and meta-analysis included 91 primary-augmentation studies and 51,524 patients. Its pooled rates refer to Baker grade III/IV contracture at the latest follow-up reported by each study, and studies needed at least 12 months of follow-up for this outcome. It reported pooled contracture rates of 6.85% for subglandular, 2.80% for subfascial, 1.99% for dual-plane and 1.83% for submuscular placement. The review reports these pooled rates. A direct comparison found higher risk for subglandular than submuscular placement (RR 2.84; 95% CI 1.05–7.72; P=.041). However, the review combined 2 randomised trials with 22 retrospective cohorts, 17 prospective cohorts and 50 case series. Follow-up and implant surface differed across groups, and all subfascial implants in the dataset were textured. The authors cautioned that confounding and temporal changes limit interpretation of these pooled rates. Alderhali and colleagues.

Reconstruction evidence must be kept separate. A 2021 narrative review notes that radiation after mastectomy can be associated with substantially higher contracture rates in reconstruction cohorts. That does not provide a rate for primary cosmetic augmentation: radiotherapy, mastectomy tissue and reconstructive procedures change the population and baseline risk. Safran and colleagues.

Does implant pocket position change the risk?

The pocket plane is one part of the evidence, but published comparisons do not isolate it consistently from implant surface and other operative choices. In augmentation, subglandular placement sits behind the breast gland and in front of the pectoral muscle; subfascial placement is beneath the pectoral fascia; submuscular placement is beneath the muscle; and dual-plane placement combines muscle coverage with a lower-pole release. Each position has other trade-offs, so a contracture statistic alone cannot choose a plane for an individual.

The 2026 review above found higher pooled rates with subglandular than with submuscular placement, but it also found that surface types were unevenly distributed: subfascial cohorts used textured implants exclusively, while other planes had mixtures of smooth, textured and polyurethane devices. The authors noted that surface could partly explain apparent plane differences. See the review methods and results.

A separate 2026 systematic review specifically stratified subfascial and subglandular studies by surface. It included 33 studies; cohorts ranged from 7 to 5,059 patients, and follow-up ranged from four days to ten years. For smooth implants, the pooled contracture rates were 17.1% in subglandular and 7.2% in subfascial pockets, but the difference was not statistically significant (P=.13). For textured implants, rates were 3.7% and 0.9%, respectively, also not significant (P=.08). Among studies published since 2015, smooth-implant rates were 8.2% and 10.3%, with no statistically significant difference reported. Most included studies had moderate or serious risk of bias, chiefly from confounding and missing data. The review concluded that older apparent subfascial advantages may reflect textured-implant cohorts; it did not prove the planes equivalent. Abbott and colleagues. The pooled contracture findings do not make textured implants a preferred choice: the FDA says BIA-ALCL risk is higher with textured than smooth-surface implants. Contracture estimates alone cannot determine implant surface choice. FDA information on BIA-ALCL.

An earlier 2024 review of ten studies (three randomised trials and seven comparative cohorts) reported lower contracture with subfascial than subglandular placement, but rated all included studies at high risk of bias. Yuan and colleagues. The different conclusion from the surface-stratified 2026 review illustrates why the implant type and study quality matter. Neither pooled result is a guaranteed outcome for a particular person.

One small prospective randomised study offers longer follow-up but cannot settle the question. Graf and colleagues studied 20 patients in a randomised, blinded prospective comparison of subfascial and subglandular placement. The accessible abstract reports five-year assessments and favoured subfascial placement for breast contour and shape. The accessible abstract does not establish a dependable severe-contracture effect estimate. All implants were textured, and the sample was very small; the study estimates pocket comparisons in that textured-implant setting and cannot establish results for smooth implants. Graf and colleagues.

Can contracture be prevented?

No technique can promise prevention. Because infection, haematoma and seroma have been associated with contracture, published reviews discuss careful infection-control practices and attention to bleeding and wound complications. They do not establish that one irrigation solution, insertion device, incision or postoperative routine eliminates the risk.

For example, a retrospective cohort using prospectively collected quality-assurance data compared saline irrigation with a triple-antibiotic solution in 55 people having primary augmentation. Contracture was recorded in 3.6% of the saline group (28 patients; mean follow-up 2.8 years) and 3.7% of the antibiotic group (27 patients; mean follow-up 2.6 years); the difference was not significant (P=.97), and severity did not differ significantly (P=.39). The sample was too small to establish that the treatments are equivalent or to exclude a meaningful difference. A separate 10-year manufacturer dataset found an association between antibiotic irrigation and contracture, but that observational result is also vulnerable to confounding. Together, these findings do not support presenting antibiotic irrigation as a proven preventive measure. Drinane and colleagues report the small cohort; the Sientra analysis reports the observational association.

A 2021 review describes postoperative massage as unproven for preventing contracture. Safran and colleagues. Do not start massage, medication or other treatment based on this article; discuss any postoperative instructions with the treating team. Device labelling, approved products and clinical practice vary by jurisdiction. The FDA says it has not cleared or approved a device to treat or reduce contracture incidence.

Recognising a change and arranging follow-up

Possible changes include increasing firmness, a breast that feels tight, a change in shape or position, visible distortion, or pain. The FDA's Baker scale describes four clinical grades: Grade I is soft and natural in appearance; Grade II is slightly firm but looks normal; Grade III is firm and looks abnormal; and Grade IV is hard, painful and looks abnormal. Grades III and IV are considered severe and may require further treatment. A grade is assigned through clinical assessment; it is not a self-test. FDA grading information.

Arrange an assessment with the clinician responsible for your implant care if you notice a new or progressive change. Sudden swelling, persistent pain, a lump or fluid around an implant also warrants prompt medical evaluation because several conditions can cause these symptoms. Symptoms alone cannot identify contracture or distinguish it from implant rupture, infection, fluid collection or another problem. The FDA lists contracture among several implant complications.

Follow-up should be based on the implant, symptoms, personal history and local guidance. Imaging recommendations for silicone implant rupture are a separate issue from diagnosing contracture; a normal physical examination cannot reliably exclude every silent rupture. Keep device and operative records, ask whom to contact if symptoms change, and clarify what follow-up is recommended for your specific implant and country. Do not delay a clinical review to compare commercial information. If a clinician recommends considering other breast procedures, the breast aesthetics package category is a general catalogue of options; it does not indicate that a package treats contracture or includes follow-up.

Questions to take to a consultation

• What diagnosis best explains the change, and what Baker grade, if any, do you assign?
• Which implant do I have, including its surface and age, and how does that affect the evidence relevant to me?
• Is the evidence you are using about primary augmentation, reconstruction or revision, and how closely does that population match my situation?
• What are the likely benefits, recurrence risks and trade-offs of each proposed option, including the extent of capsule removal or a pocket change?
• What follow-up is recommended, whom should I contact if symptoms change, and how quickly should I be assessed?

A systematic review of 34 studies of revision augmentation found that all were observational and that high-level evidence for a single contracture operation remains limited. Implant exchange and a change of pocket may help reduce recurrence, while evidence about the extent of capsule removal is less conclusive. These findings support an individual clinical discussion; they do not establish one standard operation for everyone. Boyd and colleagues (2024).

When a treating clinician discusses implant exchange, the separate breast implant replacement cost in Turkey page provides commercial pricing information. If the discussion concerns a broader revision operation, the breast revision surgery cost in Turkey page is the relevant commercial overview. Neither page establishes whether surgery is clinically indicated.

Study details and access

The evidence summarised here includes systematic reviews, a small randomised prospective study, a manufacturer-specific long-term analysis, a small retrospective cohort, a narrative review and US regulatory information. These sources answer different questions and should not be read as a single head-to-head trial. Most reported estimates concern primary cosmetic augmentation; evidence about reconstruction or revision is identified separately.

Full text was accessible for the 2026 broad pocket-plane review, the surface-stratified 2026 review, the 2021 pathophysiology review and the FDA information page. PubMed abstracts were accessible for the 2021 randomised study, 2016 irrigation cohort, 2024 pocket-plane review and 2024 contracture-management review; the 2018 Sientra article was additionally verified in a full journal-PDF copy. Full text was not verified for the remaining abstract-only records.

Just Clinic Istanbul is an independent marketing and lead-generation platform, not a healthcare provider or medical tourism intermediary. Enquiries may be shared with authorised healthcare partners with consent. This article is general research information and does not diagnose a complication or recommend a treatment for an individual.

References

1. Alderhali R, Jamel WA, Dehnadi S, Seth I, Khajuria A. Implant Pocket Plane Selection in Primary Breast Augmentation: A Meta-Analysis and Systematic Review of Complication Profiles. Aesthetic Plastic Surgery. Published online 26 February 2026; 2026 Jun;50:3979–3987. doi: 10.1007/s00266-026-05706-5. PMID 41748776. Full open-access text.
2. Abbott EN, Johnson J, Dorjsuren N, Savitz BL, Giannas E, Gutama BW, Maxwell GP, Perdikis G, Strock LL, Gabriel A. Capsular Contracture Rates in Subfascial and Subglandular Breast Augmentation With Smooth vs Textured Implants. Aesthetic Surgery Journal. Published online 23 January 2026; 2026 Sep;46(9):979–992. doi: 10.1093/asj/sjag017. PMID 41572725. Open full text: PubMed Central.
3. Graf RM, Maluf Junior I, de Paula DR, Ono MCC, Urban LABD, Freitas RS. Subfascial versus Subglandular Breast Augmentation: A Randomized Prospective Evaluation Considering a 5-Year Follow-Up. Plastic and Reconstructive Surgery. 2021 Oct;148(4):760–770. doi: 10.1097/PRS.0000000000008384. PMID 34550930. Abstract accessed; full text not verified as accessible.
4. Calobrace MB, Stevens WG, Capizzi PJ, Cohen R, Godinez T, Beckstrand M. Risk Factor Analysis for Capsular Contracture: A 10-Year Sientra Study Using Round, Smooth, and Textured Implants for Breast Augmentation. Plastic and Reconstructive Surgery. 2018 Apr;141(4S, Sientra Shaped and Round Cohesive Gel Implants):20S–28S. doi: 10.1097/PRS.0000000000004351. PMID 29595715. Full article PDF copy: journal article.
5. Drinane JJ, Kortes MJ, Bergman RS, Folkers BL. Evaluation of Antibiotic Irrigation Versus Saline Irrigation in Reducing the Long-Term Incidence and Severity of Capsular Contraction After Primary Augmentation Mammoplasty. Annals of Plastic Surgery. 2016 Jan;77(1):32–36. doi: 10.1097/SAP.0000000000000302. PMID 25144414. Abstract accessed; full text not verified as accessible.
6. Safran T, Nepon H, Chu CK, Winocour S, Murphy AM, Davison PG, Dionisopolos T, Vorstenbosch J. Current Concepts in Capsular Contracture: Pathophysiology, Prevention, and Management. Seminars in Plastic Surgery. Published online 13 July 2021; 2021 Aug;35(3):189–197. doi: 10.1055/s-0041-1731793. PMID 34526867. Open full text.
7. Yuan M, Kim P, Gallo L, Austin RE, Lista F, Ahmad J. Outcomes in Subfascial Versus Subglandular Planes in Breast Augmentation: A Systematic Review and Meta-analysis. Aesthetic Surgery Journal. Published online 3 June 2024; 2024 Aug 20;44(9):NP639–NP644. doi: 10.1093/asj/sjae118. PMID 38825810. Abstract accessed; full text not verified as accessible.
8. Boyd CJ, Chiodo MV, Lisiecki JL, Wagner RD, Rohrich RJ. Systematic Review of Capsular Contracture Management following Breast Augmentation: An Update. Plastic and Reconstructive Surgery. Published online 7 March 2023; 2024 Feb;153(2):303e–321e. doi: 10.1097/PRS.0000000000010358. PMID 36877620. Abstract accessed; full text not verified as accessible.
9. U.S. Food and Drug Administration. Risks and Complications of Breast Implants. Page updated 14 December 2023. FDA information. Regulatory information, not a clinical study.
10. U.S. Food and Drug Administration. Questions and Answers about Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). FDA information. Regulatory information, not a clinical study.